Endoscopic resection and ablation versus esophagectomy for high-grade dysplasia and intramucosal adenocarcinoma

Zehetner, Jörg; DeMeester, Steven R.; Hagen, Jeffrey A.; Ayazi, Shahin; Augustin, Florian; Lipham, John C.; DeMeester, Tom R.

doi:10.1016/j.jtcvs.2010.08.058

Cited by 112 publications

(77 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite significant investment and advances in the treatment method of cancer, the overall survival for advanced and metastatic cancer is still poor [47,48]. Hence, further investigation in early diagnosis of cancer is required with focus on microRNAs as potential biomarkers.…”

Section: Introductionmentioning

confidence: 99%

Deregulation of miR-93 and miR-143 in human esophageal cancer

et al. 2015

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) is the second and third most common malignancy in Iranian males and females, respectively. Treatment of ESCC is largely ineffective due to lack of detection at early stages of the disease. In recent years, miRNA, a small RNA molecule, has drawn much attention to researchers as a potential biomarker for esophageal cancer. miR-93 and miR-143 are two miRNA molecules reported to be frequently deregulated in various cancers, including prostate, stomach, cervix, and etc. The purpose of this study was to investigate the expression levels of these miRNAs and evaluate their diagnostic and therapeutic potential in esophageal squamous cell carcinoma. In this study, total RNA was extracted from 30 tumor tissues and 30 nontumor tissues of esophageal tumor margins, using RNX-plus solution. After validating the quality and quantity of total RNA, cDNAs of interest were synthesized using microRNA-specific cDNA Synthesis Kit. The expression level of miR-93 and miR-143 was evaluated using quantitative real-time PCR with miRNA-specific primers. Finally, the obtained data was analyzed by SPSS ver.20 software and paired t test was performed to observe the significance of difference between groups. The expression level of miR-93 was significantly increased and of miR-143 was significantly decreased in most of the examined tumor tissues, compared to nontumor tissues. Also, our findings did not detect correlation between mir-93 and mir-143 expressions in regard to stage and grade of the samples. These findings suggest that the deregulation of these miRNAs may play an important role in esophageal squamous cell carcinoma. Both miR-93 and miR-143 might be used as potential biomarkers in esophageal squamous cell carcinoma. However, more studies with large population of samples are necessary.

show abstract

Section: Introductionmentioning

confidence: 99%

Deregulation of miR-93 and miR-143 in human esophageal cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…E ndoscopic therapy has recently become an accepted first-line treatment for high-grade dysplasia (HGD) and intramucosal cancer (IMC) [1]. Two randomized controlled trials [2,3] and multiple case series [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] have demonstrated low morbidity, low rates of progression to esophageal cancer, and high rates of successful disease eradication with radiofrequency ablation (RFA) or endoscopic mucosal resection (EMR), or both. However, little is known about the outcomes of patients in whom the dysplastic cells persist, those in whom there is recurrence of the dysplasia, or those in whom there is progression from dysplasia to cancer.…”

mentioning

confidence: 99%

Outcomes in Patients Who Have Failed Endoscopic Therapy for Dysplastic Barrett’s Metaplasia or Early Esophageal Cancer

Hunt¹,

Louie²,

Schembre³

et al. 2013

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

“…79 There are no prospective trials comparing outcomes of endoscopic therapy (resection and/or ablation) with surgical therapy (esophagectomy) for BE with HGD, although a number of retrospective trials have been conducted. 50,82,83 Put together, these experiences did not demonstrate a survival difference for either surgery or ablation with or without resection, although early mortality was higher in the surgical group. There was significant treatment failure observed in the endotherapy groups as 6-20% of patients developed new or metachronous cancer.…”

Section: Management Of Be With Lgdmentioning

confidence: 70%

Barrett’s Esophagus: A Review of the Literature

Gilbert

Luna

Harrison

et al. 2011

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

Barrett's esophagus (BE) is the premalignant lesion of esophageal adenocarcinoma (EAC) defined as specialized intestinal metaplasia of the tubular esophagus that results from chronic gastroesophageal reflux. Which patients are at risk of having BE and which are at further risk of developing EAC has yet to be fully established. Many aspects of the management of BE have changed considerably in the past 5 years alone. The aim of this review is to define the critical elements necessary to effectively manage individuals with BE. The general prevalence of BE is estimated at 1.6-3% and follows a demographic distribution similar to EAC. Both short-segment (<3 cm) and long-segment (≥3 cm) BE confer a significant risk for EAC that is increased by the development of dysplasia. The treatment for flat high-grade dysplasia is endoscopic radiofrequency ablation therapy. The benefits of ablation for non-dysplastic BE and BE with low-grade dysplasia have yet to be validated. By understanding the intricacies of the development, screening, surveillance, and treatment of BE, new insights will be gained into the prevention and early detection of EAC that may ultimately lead to a reduction in morbidity and mortality in this patient population.

show abstract

Endoscopic resection and ablation versus esophagectomy for high-grade dysplasia and intramucosal adenocarcinoma

Cited by 112 publications

References 23 publications

Deregulation of miR-93 and miR-143 in human esophageal cancer

Deregulation of miR-93 and miR-143 in human esophageal cancer

Outcomes in Patients Who Have Failed Endoscopic Therapy for Dysplastic Barrett’s Metaplasia or Early Esophageal Cancer

Barrett’s Esophagus: A Review of the Literature

Contact Info

Product

Resources

About